Welcome to our dedicated page for Align Technology news (Ticker: ALGN), a resource for investors and traders seeking the latest updates and insights on Align Technology stock.
Align Technology reports developments in digital orthodontics and restorative dentistry through its Invisalign System of clear aligners, iTero intraoral scanners, exocad CAD/CAM software and the Align Digital Platform. Company news commonly covers product and workflow updates for clear-aligner treatment planning, intraoral scanning, 3D visualization and digitally connected dental practices.
Recurring updates also include quarterly and annual operating results, clear-aligner shipment and channel trends, regional demand, foreign-exchange effects, stock repurchase activity, financial-conference participation and governance or shareholder-voting matters. Other announcements describe clinical education, professional collaborations and access-to-care initiatives involving orthodontists, general practitioner dentists and dental research organizations.
Align Technology (Nasdaq: ALGN) announced multiple new features across its integrated Align™ Digital Platform to enhance Invisalign® treatment planning, diagnostics, and patient engagement. Updates span Align™ Oral Health Suite, Invisalign® Outcome Simulator Pro, ClinCheck® 3D Tissue Animation, iTero™ Design Suite, and Invisalign Smile Architect™.
Align Oral Health Suite now integrates AI-powered Align™ X-ray Insights and a gumline visualization tool to help doctors explain interproximal cavities and potential gum recession. Invisalign Outcome Simulator Pro adds Arch control and an Occlusogram for in‑face, interactive treatment simulations. A new ClinCheck 3D Tissue Animation feature lets doctors simulate facial soft tissue changes by the end of Invisalign treatment, supporting aesthetic-focused planning.
Workflow enhancements include AI-powered crown & bridge and splint design in iTero Design Suite, plus new preferences templates and Dual Flex Rx options in Invisalign Smile Architect to streamline complex ortho‑restorative cases. Align also highlights recent additions such as the Invisalign Specifix™ Attachment System, digitally integrated buttons, an Invisalign Palatal Expander System with integrated hooks, and a custom trimline option for Invisalign clear aligners.
Align Technology (Nasdaq: ALGN) has been named title sponsor of Operation Smile’s 34th International Student Leadership Conference (ISLC) 2026 in Bangkok, Thailand, from July 17–23, marking its sixth consecutive year in this role.
According to Operation Smile, Align has contributed more than $2 million over six years to student programs and nearly $3.8 million in total to support student and surgical initiatives. ISLC 2026 will host about 280 high school and university participants from 37 countries, including roughly 100 Align Scholar full-scholarship recipients, many with cleft conditions and from low- and middle-income countries.
Align Technology (Nasdaq: ALGN) will report Q2 2026 financial results on Wednesday, July 29, 2026, after market close. Results will be posted at 4:00 p.m. ET on the company’s investor relations website.
A conference call and live audio webcast to discuss results will begin at 4:30 p.m. ET, with an archived webcast available for one month.
Summary not available.
Align Technology (Nasdaq: ALGN) announced a board leadership transition. C. Raymond Larkin Jr. will retire as Chairman on July 1, 2026 after over 20 years on the board, remaining as director and Nominating and Governance Committee member through December 31, 2026 to support the transition.
Kevin Conroy, an independent director since December 2023 and Chair of the Compensation and Human Capital Committee since January 2026, will become Chairman on July 1, 2026. According to Align, Conroy brings extensive healthcare, technology, and strategic experience, including service as CEO of Exact Sciences prior to its acquisition by Abbott Laboratories in March 2026.
Align Technology (Nasdaq: ALGN) awarded $300,000 in research grants to twelve universities worldwide under its fifteenth Annual Research Award Program. Projects span the Americas, Europe, and Asia Pacific and focus on topics such as apical root resorption, aligner-based expansion, white spot lesions, retention stability, and enamel characteristics during aligner treatment.
According to Align Technology, applications were blind-reviewed by an independent academic committee before final selection. The company highlights this program as part of its support for scientific research in orthodontics and dentistry.
Align Technology (Nasdaq: ALGN) plans a new multi-million dollar manufacturing facility in Hyderabad, India, expected to start operations in 2027. The company plans to invest approximately $200 million in capital and operational expenses over several years and create 300+ direct jobs.
The Hyderabad site will be Align’s first manufacturing facility in India and its fourth globally, aimed at supporting high-growth markets like India and the Asia-Pacific region, improving supply chain resilience, and enhancing localized service for Invisalign-trained doctors. The facility is expected to be margin accretive in its first year of operation and falls within Align’s 2026 capital equipment guidance.
Align Technology (Nasdaq: ALGN) hosted the 2026 Invisalign EMEA Ortho Summit in Barcelona, gathering about 400 orthodontists from Europe, the Middle East, and Africa. The three-day event showcased integrated digital orthodontic solutions, including Invisalign Specifix Attachment System, integrated buttons, enhanced Palatal Expander features, custom trimlines, and 3D Soft Tissue Animation.
Align Technology (Nasdaq: ALGN) will present at several upcoming investor conferences, including Stifel, William Blair, Jefferies, and Goldman Sachs events between May 28 and June 8, 2026.
All presentations will be webcast live and archived for about one month on Align's investor relations website.
Align Technology (Nasdaq: ALGN) announced a $200.0 million open‑market repurchase of common stock under its existing $1.0 billion buyback program approved April 2025. Repurchases will use a Rule 10b5-1 trading plan, be funded with cash on hand, and are expected to complete by October 2026.
As of March 31, 2026, Align reported 71.6 million shares outstanding and $1,059.8 million in cash and cash equivalents, including $206.6 million held domestically allocated to support the repurchases.